Clinical trials: neoadjuvant therapy
Liver Transplantation, Thymoglobulin
rATG Induction and Tacrolimus Monotherapy in Pediatric Liver Transplantation
This open-label clinical trial will evaluate the pharmacodynamics, pharmacogenomics and early efficacy and safety of steroid-free Tacrolimus (TAC) monotherapy and its minimization after induction with rabbit, anti-human thymocyte…
- Conditions
- Liver Transplantation, Thymoglobulin, Rejection
- Trial name
- NCT01207141
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Pittsburgh
Esophageal Cancer
Defining the Radiotherapy Dose and Volume Parameters Affecting Postoperative Complications in Esophageal Cancer Patients
The purpose of this study is to identify features of the cumulative dose-volume histogram (DVH) for patients treated with trimodality therapy in oesophageal cancer and correlate these with postoperative complications.
- Trial name
- NCT02323776
- Testing
- Trimodality protocol
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Maastricht Radiation Oncology
HNSCC
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
This is a Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT04169074
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Arizona
Breast Cancer, Chemotherapy Effect
Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer
Introduction: Neoadjuvant chemotherapy (NACT) has been the standard therapy for treating patients with locally advanced breast cancer (LABC). Doxorubicin-based regimen showed a clinical response for 70-80%.
- Trial name
- NCT04418089
- Testing
- Simvastatin 40mg
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Indonesia
Bladder Cancer, Quality of Life
Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients
Among bladder cancer, the majority of them (70%) are non-muscle-invasive bladder cancer (NMIBC). The survival time is even longer in NMIBC. Patients with NMIBC receive surgery or transurethral resection of bladder tumor (TURBT).
- Trial name
- NCT05739968
- Testing
- Usual care + oncology case manager (OCM) care, Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
NSCLC
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
This study evaluates the preliminary efficacy and safety of adjuvant therapy with liquid tumor-infiltrating lymphocytes (L-TIL) in combination with tislelizumab in patients with resectable stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07330037
- Testing
- L-TIL cells injection, Tislelizumab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ovarian Cancer
Role of Laparoscopy in Assessing Resectability of Ovarian Cancer
Aim of Work is Prevention of unnecessary laparotomies and failed attempts to perform optimal cytoreduction in women with advanced ovarian cancer.
- Trial name
- NCT05564234
- Testing
- laparoscopy then primary cytoreductive surgery, laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Zagazig University
Pediatric Brain Stem Glioma
Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children
Hypofractionated radiotherapy reduce the patient and family burden through decreasing the overall treatment time. This study is to evaluate the clinical end results of the hypofractionated radiotherapy in DIPG compared to the…
- Trial name
- NCT01635140
- Testing
- Hypofractionated radiotherapy, Conventional arm
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Neuroblastoma
Combination Chemotherapy in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003093
- Testing
- filgrastim, sargramostim, carboplatin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia
Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL)
Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood and long-term survival has risen to above 90%, but 1-4% of treated patients die from infections.
- Trial name
- NCT04322084
- Testing
- Wearable Sensors
- Where
- United States
- Sponsor
- St. Jude Children's Research Hospital
Breast Cancer
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant or tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00126464
- Testing
- fulvestrant, tamoxifen citrate, conventional surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
Mantle Cell Lymphoma (MCL)
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
This multicenter, open-label, trial aims to evaluate the efficacy and safety of orelabrutinib plus lisaftoclax and rituximab in patients with high-risk mantle cell lymphoma (MCL).
- Trial name
- NCT07272499
- Testing
- Orelabrutinib, Rituximab (R), Lisaftoclax (APG-2575)
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Ruijin Hospital
Neuroblastoma
Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00025428
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 100 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy
The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients.
- Conditions
- Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology
- Trial name
- NCT07633236
- Testing
- OLANZapine 2.5 MG
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Breast Cancer
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
The goal of this clinical research study is to find out if adding local therapy (surgery and/or radiation) to standard therapy (chemotherapy or endocrine therapy) in the treatment of patients with metastatic breast cancer can…
- Trial name
- NCT00929214
- Testing
- Standard Therapy, Local Therapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Breast Cancer
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk to recurrence and metastasis.
- Trial name
- NeraHER2 (NCT06693024)
- Testing
- neratinib
- Where
- China
- Volunteers
- 2,806 people
- Sponsor
- Shu Wang
Rectum Cancer
MRI Split Scar Sign as a Predictor to Complete Pathologic Response After Neoadjuvant Chemoradiation in Rectal Cancer
Patients with middle or low rectal cancer who receive neoadjuvant chemoradiation and achieve complete clinical response while their pelvic MRI have split scar sign are included.
- Trial name
- NCT04745091
- Testing
- total mesorectal excision
- Volunteers
- 20 people
- Sponsor
- Alexandria University
Acute Lymphoblastic Leukemia, Immunotherapy
Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
This trial is a non-blinded, single-center, open-label, single-arm clinical study to evaluate a full-course immunotherapy regimen in patients with B-cell acute lymphoblastic leukemia (B-ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin
- Trial name
- NCT06985485
- Testing
- Blinatumomab and Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 26 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Osteosarcoma of Pelvis
Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum
To study the effect of the timing of surgery on outcome of patients with nonmetastatic osteosarcoma of pelvis and sacrum.
- Trial name
- NCT03360760
- Testing
- Doxorubicin, Cisplatin, Methotrexate
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Neuroblastoma
Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma
RATIONALE: Drugs used in chemotherapy, such as vincristine, cyclophosphamide, cisplatin, etoposide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00416676
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Volunteers
- 30 people
- Sponsor
- Children's Cancer and Leukaemia Group